dc.contributor.author |
Baichan, P
|
|
dc.contributor.author |
Naicker, Previn
|
|
dc.contributor.author |
Devar, J
|
|
dc.contributor.author |
Smith, M
|
|
dc.contributor.author |
Nweke, EE
|
|
dc.contributor.editor |
Shukla, VK |
|
dc.contributor.editor |
Pandey, M |
|
dc.contributor.editor |
Dixit, R |
|
dc.date.accessioned |
2023-05-23T06:34:22Z |
|
dc.date.available |
2023-05-23T06:34:22Z |
|
dc.date.issued |
2023-01 |
|
dc.identifier.citation |
Baichan, P., Naicker, P., Devar, J., Smith, M. & Nweke, E. 2023. A look at emerging therapeutic targets for gallbladder cancer: A multi-Omics approach. In <i>Gallbladder Cancer: Current Treatment Options</i>. V. Shukla, M. Pandey & R. Dixit, Eds. S.l.: Springer Nature. http://hdl.handle.net/10204/12788 . |
en_ZA |
dc.identifier.isbn |
978-981-19-6441-1 |
|
dc.identifier.isbn |
978-981-19-6442-8 |
|
dc.identifier.uri |
https://doi.org/10.1007/978-981-19-6442-8_10
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/12788
|
|
dc.description.abstract |
Gallbladder cancer (GBC) is the most frequent biliary tract cancer (including cancers of the intra- and extrahepatic biliary tree). Like many biliary tract carcinomas, GBC is identified by late diagnosis, poor prognosis, and ineffective treatment. Surgery remains the most effective management strategy. Nevertheless, the 5-year survival rate of GBC ranges from approximately 0 to 12%, thus better treatment modalities are required. Over recent years, a multi-omics approach has been implored in the discovery of therapeutic biomarkers. In this chapter, we review known chemotherapeutic drugs used in GBC treatment. Then, we extensively analyze the discovery of several proteins, genes, microRNAs, mutations, metabolites, and microbes whose expressions are dysregulated in GBC. Importantly, we highlight their potential use as therapeutic biomarkers due to their functions in GBC progression. Lastly, we review emerging strategies such as immunotherapy and their potential of improving patient survival. |
en_US |
dc.format |
Abstract |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Springer Nature |
en_US |
dc.relation.uri |
https://link.springer.com/book/10.1007/978-981-19-6442-8 |
en_US |
dc.source |
Gallbladder Cancer: Current Treatment Options |
en_US |
dc.subject |
Biomarkers |
en_US |
dc.subject |
Chemotherapy |
en_US |
dc.subject |
Clinical trials |
en_US |
dc.subject |
Gallbladder cancer |
en_US |
dc.subject |
Multi-omics |
en_US |
dc.title |
A look at emerging therapeutic targets for gallbladder cancer: A multi-omics approach |
en_US |
dc.type |
Book Chapter |
en_US |
dc.description.pages |
161-175 |
en_US |
dc.description.placeofpublication |
Singapore Pte Ltd |
en_US |
dc.description.note |
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website: https://link.springer.com/book/10.1007/978-981-19-6442-8 |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.impactarea |
Human Molecular Diagnostics |
en_US |
dc.identifier.apacitation |
Baichan, P., Naicker, P., Devar, J., Smith, M., & Nweke, E. (2023). A look at emerging therapeutic targets for gallbladder cancer: A multi-Omics approach. In V. Shukla, M. Pandey & R. Dixit. (Eds.), <i>Gallbladder Cancer: Current Treatment Options</i> Springer Nature. http://hdl.handle.net/10204/12788 |
en_ZA |
dc.identifier.chicagocitation |
Baichan, P, Previn Naicker, J Devar, M Smith, and EE Nweke. "A look at emerging therapeutic targets for gallbladder cancer: A multi-omics approach" In <i>GALLBLADDER CANCER: CURRENT TREATMENT OPTIONS</i>, edited by VK Shukla. n.p.: Springer Nature. 2023. http://hdl.handle.net/10204/12788. |
en_ZA |
dc.identifier.vancouvercitation |
Baichan P, Naicker P, Devar J, Smith M, Nweke E. A look at emerging therapeutic targets for gallbladder cancer: A multi-omics approach. In Shukla V, Pandey M, Dixit R, editors.. Gallbladder Cancer: Current Treatment Options. [place unknown]: Springer Nature; 2023. [cited yyyy month dd]. http://hdl.handle.net/10204/12788. |
en_ZA |
dc.identifier.ris |
TY - Book Chapter
AU - Baichan, P
AU - Naicker, Previn
AU - Devar, J
AU - Smith, M
AU - Nweke, EE
AB - Gallbladder cancer (GBC) is the most frequent biliary tract cancer (including cancers of the intra- and extrahepatic biliary tree). Like many biliary tract carcinomas, GBC is identified by late diagnosis, poor prognosis, and ineffective treatment. Surgery remains the most effective management strategy. Nevertheless, the 5-year survival rate of GBC ranges from approximately 0 to 12%, thus better treatment modalities are required. Over recent years, a multi-omics approach has been implored in the discovery of therapeutic biomarkers. In this chapter, we review known chemotherapeutic drugs used in GBC treatment. Then, we extensively analyze the discovery of several proteins, genes, microRNAs, mutations, metabolites, and microbes whose expressions are dysregulated in GBC. Importantly, we highlight their potential use as therapeutic biomarkers due to their functions in GBC progression. Lastly, we review emerging strategies such as immunotherapy and their potential of improving patient survival.
DA - 2023-01
DB - ResearchSpace
DP - CSIR
ED - Shukla, VK
ED - Pandey, M
ED - Dixit, R
J1 - Gallbladder Cancer: Current Treatment Options
KW - Biomarkers
KW - Chemotherapy
KW - Clinical trials
KW - Gallbladder cancer
KW - Multi-omics
LK - https://researchspace.csir.co.za
PY - 2023
SM - 978-981-19-6441-1
SM - 978-981-19-6442-8
T1 - A look at emerging therapeutic targets for gallbladder cancer: A multi-omics approach
TI - A look at emerging therapeutic targets for gallbladder cancer: A multi-omics approach
UR - http://hdl.handle.net/10204/12788
ER -
|
en_ZA |
dc.identifier.worklist |
26527 |
en_US |